Evidence map›Paper›PMID 41801340›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Prevention of rheumatoid arthritis : Current study results on the therapeutic intervention in patients at risk].

Ulf Wagner

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ulf WagnerKlinik für Endokrinologie, Nephrologie und Rheumatologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland. ulf.wagner@medizin.uni-leipzig.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preventive interventions in patients at increased risk of developing rheumatoid arthritis (RA) have gained in importance in recent years. Current study data show that early, targeted immunomodulatory treatment in carefully stratified high-risk patients can delay the onset of clinically manifest RA and reduce the disease burden in the sense of secondary prevention. This review summarizes the evidence from four key studies and discusses their clinical implications, taking the particular legal and practical challenges associated with off-label use into account.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAbataceptAnti-Citrullinated Protein AntibodiesHumansImmunoconjugatesMethotrexateRisk FactorsAbataceptAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsImmunoconjugatesMethotrexateAbataceptAnti-citrullinated protein antibodies (ACPA)ArthralgiaMethotrexateOff-label use

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.